"Alzheimer's is one of the seminal public health issues of our time; the fiscal and social implications cannot be ignored," said Anne Whitaker , President, North America Pharmaceuticals, Sanofi. "From a health perspective and a business perspective, our only option is to pursue a comprehensive framework that includes partnerships, research investments, business models and policy changes to turn this pending crisis into opportunity."
Alzheimer's and dementia is a global public health priority that requires a global solution. According to the World Health Organization and the Alzheimer's Disease International 2012 Dementia Report, in 2010, there were approximately 36 million people worldwide suffering from dementia – most diagnosed over the age of 60 – and that number will spike to 115 million by 2050. Further, the total worldwide costs of dementia, including Alzheimer's disease, were estimated to exceed $600 billion, which is equivalent to one percent of global gross domestic product (GDP). Combined with a lack of treatment options and the aging of the global population, both prevalence and cost will skyrocket without proper attention and investment.
"CEOi intends to utilize our collective expertise across the health, diagnostic, medical, financial services and t
|SOURCE The Global CEO Initiative on Alzheimer’s Disease (CEOi)|
Copyright©2012 PR Newswire.
All rights reserved